DK2092069T3 - Modificerede opløselige fgf-receptor fc-fusioner med forbedret biologisk aktivitet - Google Patents

Modificerede opløselige fgf-receptor fc-fusioner med forbedret biologisk aktivitet

Info

Publication number
DK2092069T3
DK2092069T3 DK07866627.8T DK07866627T DK2092069T3 DK 2092069 T3 DK2092069 T3 DK 2092069T3 DK 07866627 T DK07866627 T DK 07866627T DK 2092069 T3 DK2092069 T3 DK 2092069T3
Authority
DK
Denmark
Prior art keywords
fusions
biological activity
fgf receptor
enhanced biological
modified soluble
Prior art date
Application number
DK07866627.8T
Other languages
English (en)
Inventor
Mark Nesbit
Beatrice Cameron
Francis Blanche
Sylvie Sordello
Celine Nicolazzi
Marc Trombe
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39431092&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2092069(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of DK2092069T3 publication Critical patent/DK2092069T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK07866627.8T 2006-11-28 2007-11-28 Modificerede opløselige fgf-receptor fc-fusioner med forbedret biologisk aktivitet DK2092069T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06291824 2006-11-28
EP07290042 2007-01-11
PCT/IB2007/004354 WO2008065543A2 (en) 2006-11-28 2007-11-28 Modified soluble fgf receptor fc fusions with improved biological activity

Publications (1)

Publication Number Publication Date
DK2092069T3 true DK2092069T3 (da) 2011-08-29

Family

ID=39431092

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07866627.8T DK2092069T3 (da) 2006-11-28 2007-11-28 Modificerede opløselige fgf-receptor fc-fusioner med forbedret biologisk aktivitet

Country Status (33)

Country Link
US (3) US8119770B2 (da)
EP (1) EP2092069B2 (da)
JP (1) JP2010510801A (da)
KR (1) KR20090102769A (da)
AR (1) AR063975A1 (da)
AT (1) ATE509106T1 (da)
AU (1) AU2007326985C1 (da)
BR (1) BRPI0719290A2 (da)
CA (1) CA2668932A1 (da)
CL (1) CL2007003411A1 (da)
CO (1) CO6190564A2 (da)
CR (1) CR10777A (da)
CY (1) CY1112435T1 (da)
DK (1) DK2092069T3 (da)
EA (1) EA018700B1 (da)
EC (1) ECSP099361A (da)
GT (1) GT200900137A (da)
HR (1) HRP20110503T1 (da)
IL (1) IL198480A0 (da)
MA (1) MA31143B1 (da)
MX (1) MX2009005692A (da)
MY (1) MY145914A (da)
NI (1) NI200900097A (da)
NO (1) NO20092414L (da)
PE (1) PE20081250A1 (da)
PL (1) PL2092069T3 (da)
PT (1) PT2092069E (da)
RS (1) RS51911B (da)
SI (1) SI2092069T1 (da)
SV (1) SV2009003272A (da)
TN (1) TN2009000184A1 (da)
TW (1) TW200839012A (da)
WO (1) WO2008065543A2 (da)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7850970B2 (en) 2003-08-26 2010-12-14 The Regents Of The University Of Colorado Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections
NZ565511A (en) 2005-07-22 2011-03-31 Five Prime Therapeutics Inc Compositions and methods of treating disease with FGFR fusion proteins
WO2010017198A2 (en) 2008-08-04 2010-02-11 Five Prime Therapeutics, Inc. Fgfr extracellular domain acidic region muteins
US8445445B2 (en) 2009-09-15 2013-05-21 Five Prime Therapeutics, Inc. Method of promoting hair growth using FGFR4 extracellular domains
DK2498799T3 (da) 2009-11-13 2016-12-05 Five Prime Therapeutics Inc Anvendelse af FGFR1 ECD-proteiner til behandling af cancersygdomme karakteriseret ved ligandafhængige aktiverende mutationer i FGFR2
EP2512501A4 (en) 2009-12-17 2014-01-01 Five Prime Therapeutics Inc METHODS FOR PROMOTING HAIR GROWTH USING FGFR3 EXTRACELLULAR DOMAINS
FR2958936A1 (fr) 2010-04-14 2011-10-21 Sanofi Aventis Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs
SG190788A1 (en) * 2010-11-15 2013-07-31 Five Prime Therapeutics Inc Fgfr1 extracellular domain combination therapies
AU2015258172B2 (en) * 2010-11-15 2017-01-12 Five Prime Therapeutics, Inc. Fgfr1 extracellular domain combination therapies
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
US8951972B2 (en) * 2010-12-09 2015-02-10 Five Prime Therapeutics, Inc. FGFR1 extracellular domain combination therapies for lung cancer
UY33833A (es) 2010-12-23 2012-07-31 Sanofi Sa Proteína de fusión Robo1-Fc para su uso en el tratamiento del hepatocarcinoma
AR085302A1 (es) * 2011-02-24 2013-09-18 Sanofi Sa Metodo de produccion de anticuerpos sialilados
CN102219860B (zh) * 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 FGFR-Fc融合蛋白及其用途
CN102219859B (zh) 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 拮抗血管新生诱导因子的融合蛋白及其用途
EP2723370A4 (en) * 2011-06-24 2015-06-03 Univ Colorado Regents COMPOSITIONS, PROCESS AND USE OF ALPHA-1-ANTITRYPHIN FUSION MOLECULES
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
US10016484B2 (en) 2011-11-14 2018-07-10 Five Prime Therapeutics, Inc. Methods of treating lung cancer
KR20140137347A (ko) 2012-01-10 2014-12-02 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 알파-1 안티트립신 융합 분자용 조성물, 방법 및 용도
KR20160002681A (ko) 2013-01-16 2016-01-08 인썸(인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰메디칼르) 골격 성장 지연 질환의 예방 또는 치료에 사용하기 위한 용해성 섬유아세포 성장 인자 수용체 3(fgr3) 폴리펩티드
KR20150123250A (ko) 2013-03-06 2015-11-03 제넨테크, 인크. 암 약물 내성의 치료 및 예방 방법
SG11201506088RA (en) 2013-03-11 2015-09-29 Genzyme Corp Hyperglycosylated binding polypeptides
US9957313B2 (en) 2013-03-15 2018-05-01 Remegen, Ltd. FGFR-FC fusion proteins and the use thereof
KR102049990B1 (ko) 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
JP2016524611A (ja) * 2013-05-23 2016-08-18 ファイヴ プライム セラピューティクス インク がんを治療する方法
PL3027651T3 (pl) 2013-08-01 2019-08-30 Five Prime Therapeutics, Inc. Afukozylowane przeciwciała anty-fgfr2iiib
HUE061339T2 (hu) 2014-03-19 2023-06-28 Genzyme Corp Targetáló csoportok helyspecifikus glikotechnikai átalakítása
US20230190750A1 (en) 2014-06-13 2023-06-22 Genentech, Inc. Methods of treating and preventing cancer drug resistance
EP3380523A1 (en) 2015-11-23 2018-10-03 Five Prime Therapeutics, Inc. Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
SG10202112636SA (en) 2017-05-16 2021-12-30 Five Prime Therapeutics Inc Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment
JP6967578B2 (ja) 2017-11-30 2021-11-17 グリフォルス ダイアグノステック ソリューションズ インコーポレーテッド 免疫チェックポイント阻害剤ｐｄ−１及びｐｄ−ｌ１に対する抗体治療をモニタリングするためのイムノアッセイ及び操作されたタンパク質
TWI835772B (zh) * 2018-01-26 2024-03-21 美商建南德克公司 Il-22fc融合蛋白及使用方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288856A (en) 1986-11-20 1994-02-22 Pierre Amiguet Method of isolating acid-stable, biologically active proteins
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5750375A (en) * 1988-01-22 1998-05-12 Zymogenetics, Inc. Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
US5147638A (en) 1988-12-30 1992-09-15 Oklahoma Medical Research Foundation Inhibition of tumor growth by blockade of the protein C system
US5288855A (en) * 1989-01-23 1994-02-22 Farmitalia Carlo Erba Extracellular form of the human fibroblast growth factor receptor
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5153310A (en) * 1989-02-28 1992-10-06 Du Pont Merck Pharmaceutical Company Il-2 analogs containing n-linked glycosylation sites
DK0481000T3 (da) 1989-07-06 1999-11-15 Univ California Receptorer for fibroblastvækstfaktorer
EP0529076B1 (en) * 1990-04-27 1995-12-06 Takeda Chemical Industries, Ltd. Proteins with fibroblast growth factor receptor activity
US5349053A (en) * 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
ES2204886T3 (es) 1990-07-06 2004-05-01 Gencell S.A. Receptores de factor de crecimiento fibroblastico.
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US20020045207A1 (en) * 1997-10-31 2002-04-18 Lynne A. Krummen Glycoprotein production process
DK2180007T4 (da) 1998-04-20 2017-11-27 Roche Glycart Ag Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet
AU3224700A (en) * 1999-02-08 2000-08-25 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion
US6612152B2 (en) * 1999-05-01 2003-09-02 James E. Keaton Lifting, servicing, and diagnosing automobiles
US6656738B1 (en) * 1999-11-17 2003-12-02 Bae Systems Integrated Defense Solutions Inc. Internal heater for preconcentrator
WO2002002597A2 (en) * 2000-06-30 2002-01-10 Maxygen Aps Peptide extended glycosylated polypeptides
EA013224B1 (ru) 2000-10-06 2010-04-30 Киова Хакко Кирин Ко., Лтд. Клетки, продуцирующие композиции антител
US20040110226A1 (en) * 2002-03-01 2004-06-10 Xencor Antibody optimization
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
EP1498490A4 (en) * 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING ANTIBODY COMPOSITION
EP1498491A4 (en) * 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA
EP3502133A1 (en) * 2002-09-27 2019-06-26 Xencor, Inc. Optimized fc variants and methods for their generation
US20050239088A1 (en) 2003-05-16 2005-10-27 Shepard H M Intron fusion proteins, and methods of identifying and using same
AU2004280066A1 (en) * 2003-10-09 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Genomically modified cell
DE102004022895A1 (de) 2004-05-10 2005-12-08 Adam Opel Ag Schallabsorbierendes Verkleidungselement
EP2471813B1 (en) 2004-07-15 2014-12-31 Xencor, Inc. Optimized Fc variants
US20060223147A1 (en) * 2004-08-05 2006-10-05 Kyowa Hakko Kogyo Co., Ltd., Process for producing glycoprotein composition
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
AU2006230413B8 (en) 2005-03-31 2011-01-20 Xencor, Inc Fc variants with optimized properties
US20060234347A1 (en) 2005-04-13 2006-10-19 Harding Thomas C Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
EP1746161A1 (en) * 2005-07-20 2007-01-24 Cytheris Glycosylated IL-7, preparation and uses
NZ565511A (en) * 2005-07-22 2011-03-31 Five Prime Therapeutics Inc Compositions and methods of treating disease with FGFR fusion proteins
CA2624189A1 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties

Also Published As

Publication number Publication date
TN2009000184A1 (en) 2010-10-18
US20140030265A1 (en) 2014-01-30
US8119770B2 (en) 2012-02-21
EA018700B1 (ru) 2013-10-30
AR063975A1 (es) 2009-03-04
AU2007326985A1 (en) 2008-06-05
IL198480A0 (en) 2011-08-01
HRP20110503T1 (hr) 2011-08-31
KR20090102769A (ko) 2009-09-30
SI2092069T1 (sl) 2011-09-30
WO2008065543A3 (en) 2008-08-14
MX2009005692A (es) 2009-10-12
EA200970515A1 (ru) 2009-12-30
GT200900137A (es) 2011-09-02
SV2009003272A (es) 2010-02-05
PE20081250A1 (es) 2008-10-07
CR10777A (es) 2009-07-23
US20120195851A1 (en) 2012-08-02
ECSP099361A (es) 2009-06-30
ATE509106T1 (de) 2011-05-15
CL2007003411A1 (es) 2008-07-04
MY145914A (en) 2012-05-15
JP2010510801A (ja) 2010-04-08
NO20092414L (no) 2009-08-21
PT2092069E (pt) 2011-07-29
AU2007326985B2 (en) 2013-08-15
BRPI0719290A2 (pt) 2014-02-25
CA2668932A1 (en) 2008-06-05
RS51911B (en) 2012-02-29
EP2092069A2 (en) 2009-08-26
EP2092069B2 (en) 2013-12-18
US8481487B2 (en) 2013-07-09
NI200900097A (es) 2010-01-26
PL2092069T3 (pl) 2011-10-31
WO2008065543A2 (en) 2008-06-05
EP2092069B1 (en) 2011-05-11
MA31143B1 (fr) 2010-02-01
TW200839012A (en) 2008-10-01
CO6190564A2 (es) 2010-08-19
AU2007326985C1 (en) 2014-02-20
CY1112435T1 (el) 2015-12-09
US20100061979A1 (en) 2010-03-11

Similar Documents

Publication Publication Date Title
DK2092069T3 (da) Modificerede opløselige fgf-receptor fc-fusioner med forbedret biologisk aktivitet
BRPI0720021A2 (pt) anticorpos humanos para o ligante similar á delta-4 humano
BRPI0813908A2 (pt) Seringa com mecanismo de desativar
ATE505467T1 (de) 2-aza-bicycloä3.1.0ühexanderivate als orexin- rezeptorantagonisten
DK2035447T3 (da) Polypeptid
ATE509022T1 (de) Nikotin-acetylcholin-rezeptorsubtyp-selektive diazabicycloalkanamide
DK2014652T3 (da) Aktiveringsmiddel til peroxisom-proliferator-aktiveret receptor
ATE481404T1 (de) Adenosinderivate als agonisten am a2a-rezeptor
BRPI0714291A2 (pt) Derivados de [4,5']bipirimidinil-6-4'-diamina como inibidores de proteína cinase
DE602007008831D1 (de) Cyclohexyl-sulfonamid-derivate mit h3-rezeptoraktivität
DE602007004718D1 (de) Katheter mit bogenförmigem übergangsbereich
DK2035543T3 (da) Thermoanaerobacter mathranii-stamme BG1
DE602007002261D1 (de) Beheiztes Tintenliefersystem
DK1978981T3 (da) Præparater til vaginal anvendelse
BRPI0719693A2 (pt) Sal fumarato de (alfa s, beta r)-6-bromo-alfa-[2- (demetilamino)etil]-2-metóxi-alfa-1-naftalenil-beta- fenil-3-quinolinaetanol
BRPI0912988A2 (pt) compostos bicíclicos tendo atividade no receptor cxcr4.
BRPI1011940A2 (pt) redobramento de proteínas usando um estado redox controlado quimicamente.
DE502007001650D1 (de) Turbolader mit katalytische beschichtung
DK2238110T3 (da) 5.6-bisaryl-2-pyridin-carboxamid-derivater, fremstilling heraf og terapeutisk anvendelse heraf som urotensin II-receptorantagonister
ATE454377T1 (de) 2-phenyl-6-aminocarbonylpyrimidinderivate und ihre verwendung als antagonisten am p2y12- rezeptor
BRPI0820633A2 (pt) antagonistas de receptores de il-4 muteína modificada
BRPI0811094A2 (pt) Derivados de heteroarilamida pirimidona
ATE502016T1 (de) Triazolo-ä1,5-aü-chinoline als adenosin-a3- rezeptorliganden
ZA200903134B (en) Modified soluble FGF receptor FC fusions with improved biological activity
BRPI0912889A2 (pt) implemento de escrita com clipe articulado